Interpretation of the JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease
MU Zhi-Long, JIAO Fu-Yong, XIE Kai-Sheng
Children's Hospital of Shaanxi Provincial People's Hospital/Diagnosis and Treatment Center of Kawasaki Disease of Shaanxi Province, Xi'an 710068, China
Abstract Kawasaki disease is the main cause of acquired heart disease in children. The cardiovascular sequelae of Kawasaki disease, such as coronary artery lesion and giant coronary aneurysm, have a great impact on children's physical and mental health. The Japanese Circulatory Society and the Japanese Society of Cardiac Surgery jointly released the JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease in July, 2020, which systematically introduces the advances in the diagnosis and management of cardiovascular sequelae of Kawasaki disease. The article gives an interpretation in the severity evaluation of Kawasaki disease and diagnosis, treatment and long-term management of cardiovascular sequelae in the guideline.
MU Zhi-Long,JIAO Fu-Yong,XIE Kai-Sheng. Interpretation of the JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. CJCP, 2021, 23(3): 213-220.
MU Zhi-Long,JIAO Fu-Yong,XIE Kai-Sheng. Interpretation of the JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. CJCP, 2021, 23(3): 213-220.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children[J]. Arerugi, 1967, 16(3):178-222.
[4]
Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8):1348-1407.
[5]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136(6):e137-e161.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17):e927-e999.
[8]
Gupta-Malhotra M, Gruber D, Abraham SS, et al. Atherosclerosis in survivors of Kawasaki disease[J]. J Pediatr, 2009, 155(4):572-577.
[9]
Okada T, Harada K, Okuni M. Serum HDL-cholesterol and lipoprotein fraction in Kawasaki disease (acute mucocutaneous lymph node syndrome)[J]. Jpn Circ J, 1982, 46(10):1039-1044.
[10]
JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version[J]. Circ J, 2014, 78(10):2521-2562.
[11]
Japanese Circulation Society. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome[EB/OL].[2020-08-20].
[12]
Takahashi K, Oharaseki T, Yokouchi Y. Histopathological aspects of cardiovascular lesions in Kawasaki disease[J]. Int J Rheum Dis, 2018, 21(1):31-35.
[13]
Meyer-Ter-Vehn T, Katzenberger B, Han H, et al. Lovastatin inhibits TGF-β-induced myofibroblast transdifferentiation in human tenon fibroblasts[J]. Invest Ophthalmol Vis Sci, 2008, 49(9):3955-3960.
[14]
Franco A, Shimizu C, Tremoulet AH, et al. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease[J]. Autoimmunity, 2010, 43(4):317-324.
[15]
Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system[J]. Arterioscler Thromb Vasc Biol, 2002, 22(8):1257-1266.
[16]
Nishikawa H, Miura S, Shimomura H, et al. Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis[J]. J Cardiol, 2005, 45(3):107-113.
[17]
Jennings LK. Mechanisms of platelet activation:need for new strategies to protect against platelet-mediated atherothrombosis[J]. Thromb Haemost, 2009, 102(2):248-257.
[18]
Yahata T, Suzuki C, Yoshioka A, et al. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease[J]. Circ J, 2014, 78(1):188-193.
[19]
Japanese Circulation Society. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009)[EB/OL].[2020-08-20]. https://www.j-circ.or.jp/old/guideline/pdf/JCS2009_hori_h.pdf.
[20]
Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children:primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial[J]. Circulation, 2008, 117(4):553-559.
[21]
Watanabe T. Kawasaki disease with retropharyngeal edema following a blackfly bite[J]. Case Rep Pediatr, 2014, 2014:296456.
[22]
Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events[J]. N Engl J Med, 2016, 374(7):625-635.
[23]
Hsu LL, Sarnaik S, Williams S, et al. A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease:a 2-part phase 2 study[J]. Am J Hematol, 2018, 93(12):1493-1500.
[24]
JCS Joint Working Group. Guidelines for drug therapy in pediatric patients with cardiovascular diseases (JCS 2012). Digest version[J]. Circ J, 2014, 78(2):507-533.
[25]
Japanese Circulation Society. Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017)[EB/OL].[2020-08-20]. https://j-circ.or.jp/old/guideline/pdf/JCS2017_ito_h.pdf.
[26]
Fukazawa R, Kobayashi T, Mikami M, et al. Nationwide survey of patients with giant coronary aneurysm secondary to Kawasaki disease 1999-2010 in Japan[J]. Circ J, 2017, 82(1):239-246.
[27]
Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention:a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine[J]. J Am Coll Cardiol, 2019, 73(2):214-237.
[28]
Tsuda E, Kitamura S, Cooperative Study Group of Japan. National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan[J]. Circulation, 2004, 110(11 Suppl 1):Ⅱ61-Ⅱ66.
[29]
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, et al. Thoracic and cardiovascular surgery in Japan during 2015:annual report by the Japanese Association for Thoracic Surgery[J]. Gen Thorac Cardiovasc Surg, 2018, 66(10):581-615.
[30]
Kitamura S, Tsuda E. Significance of coronary revascularization for coronary-artery obstructive lesions due to Kawasaki disease[J]. Children (Basel), 2019, 6(2):16.
